HGS’ board urges shareholders not to accept “inadequate” offer from GSK
The board of US biopharmaceutical firm Human Genome Sciences (NASDAQ:HGSI), or HGS, said on Thursday it had determined that the USD13.00 (EUR10.23) a share hostile takeover offer from British drugmaker…

